Alkermes rated at buy by Merrill

Alkermes Inc. was given a buy rating by Merrill Lynch analyst Hari Sambasivam on news that the company launched Vivitrol in the United States through a limited network of specialty providers. The analyst estimates end user sales for Vivitrol of $37.5 million in 2007, which is comparable to the patient numbers for Campral in the first year. Shares of the Cambridge, Mass.-based pharmaceutical company were down 74 cents, or 3.82%, at $18.64 on volume of 1,806,712 shares versus the three-month running average of 1,656,240 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.